Neurocrine price target raised to $154 from $150 at Oppenheimer

Oppenheimer raised the firm’s price target on Neurocrine to $154 from $150 and keeps an Outperform rating on the shares. The FDA approved Ingrezza for treatment of Huntington’s Disease chorea providing a second indication to drive revenue growth, and Oppenheimer is optimistic about the updated label which highlights Ingrezza’s competitive profile in HD chorea including efficacy, safety, tolerability, dosing convenience and other differentiating features, the analyst tells investors in a research note.